Parkinson Hastalığında Hafif Bilişsel Bozukluk ve Demans Görüntüleme.
Imaging Mild Cognitive Impairment and Dementia in Parkinson's Disease.
DOI: 10.3389/fneur.2020.00047PMID: 32082250
Imaging Mild Cognitive Impairment and Dementia in Parkinson's Disease.
DOI: 10.3389/fneur.2020.00047PMID: 32082250
Nutritional ketosis as an intervention to relieve astrogliosis: Possible therapeutic applications in the treatment of neurodegenerative and neuroprogressive disorders.
DOI: 10.1192/j.eurpsy.2019.13PMID: 32093791
Brain targeting with docosahexaenoic acid as a prospective therapy for neurodegenerative diseases and its passage across blood brain barrier.
DOI: 10.1016/j.biochi.2020.01.013PMID: 32014503
Gene therapy for neurodegenerative disorders: advances, insights and prospects.
DOI: 10.1016/j.apsb.2020.01.015PMID: 32963936
Do mobile device apps designed to support medication adherence demonstrate efficacy? A systematic review of randomised controlled trials, with meta-analysis.
DOI: 10.1136/bmjopen-2019-032045PMID: 32005778
Cognitive behavioral therapy for depression and anxiety of Parkinson's disease: A systematic review and meta-analysis.
DOI: 10.1016/j.ctcp.2020.101111PMID: 32379650
Copper Ions and Parkinson's Disease: Why Is Homeostasis So Relevant?
DOI: 10.3390/biom10020195PMID: 32013126
Neuropsychiatric Disorders in Parkinson's Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?
DOI: 10.3389/fnins.2020.00025PMID: 32063833
Targeting microglia L-type voltage-dependent calcium channels for the treatment of central nervous system disorders.
DOI: 10.1002/jnr.24585PMID: 31997405
Circadian rhythms, Neuroinflammation and Oxidative Stress in the Story of Parkinson's Disease.
DOI: 10.3390/cells9020314PMID: 32012898
Structural Diversity of Amyloid Fibrils and Advances in Their Structure Determination.
DOI: 10.1021/acs.biochem.9b01069PMID: 31967790
Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.
DOI: 10.1007/s00702-020-02150-wPMID: 31993732
Kayıtlar bilimsel kaynaklardan alınır. Bibliyografik kayıt sayısı, Türkçe çeviri veya editoryal onay sayısı değildir.